Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

June 25, 2024 9:38 am Published by

Butler J, Shah SJ […] Wolf D, Kosiborod MN; STEP-HFpEF Trial Committees and Investigators. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet 2024/403:1635-1648. doi: 10.1016/S0140-6736(24)00469-0.

Categorised in:

This post was written by sfb1425